United States Patent 5,310,912 Landscape: Scope and Claims for Iodinated Neuroprobes for Mapping Monoamine Reuptake Sites
US Patent 5,310,912 claims iodinated neuroprobes intended for mapping monoamine reuptake sites in vivo, using compounds with a broad structural Markush framework. The claims cover (i) the iodinated neuroprobe composition generically (including multiple substituent types and isotope choices) and (ii) the same scaffold with specific radioisotopes including ^123I, ^125I, and ^131I. The practical value of the estate is in how broadly the claim language reads on alternative iodine-bearing analogs and on variants where “X” is an iodine isotope, while keeping the overall “neuroprobe” and monoamine reuptake mapping purpose anchored in the claim.
What is US Patent 5,310,912 and what does it claim for monoamine reuptake mapping?
US 5,310,912 is directed to an iodinated neuroprobe “for mapping monoamine reuptake sites.” The independent claims (claims 1 and 5) recite an iodinated probe defined by a formula with Markush variables:
Claim set coverage at a high level
- Independent claims: 1 and 5
- Isotope-dependent dependent claims:
- Claim 2: ^123I
- Claim 3: ^125I
- Claim 4: ^131I
- Claim 6: ^123I
- Claim 7: ^125I
- Claim 8: ^131I
- Core functional statement: “mapping monoamine reuptake sites”
- Core chemical identity: “iodinated neuroprobe” defined by a formula with variables R, R′, X, R″1, R″2, R″3, Y
What “iodinated” means in claim construction
The claim language requires iodination through X as an “isotope of … I” option, and also allows X to be other isotopes/elements or chemical groups (F, Cl, Br, I isotopes, CH3, or Sn(R″1R″2R″3)). This makes the claim conceptually a radioisotope-capable scaffold rather than a single fixed iodine compound.
How broad are the Markush structural variables in claims 1 and 5?
The breadth of claim scope is driven by the Markush positions. Claims 1 and 5 share the same variable definitions for the key positions, with the main difference being the substitution pattern in the stated formula (claims 1 vs 5 show two different recited structures in the prompt’s formatting). The variable definitions you provided allow analysis of breadth even without re-drawing the exact scaffold.
Variable-by-variable scope
R
- “R = a monofluoroalkyl group including n F where n = 18 or 19”
- This reads as a constrained option:
- R is a monofluoroalkyl substituent
- with a fluorinated alkyl chain length where n is 18 or 19
- Functionally, this anchors the claim to long-chain fluorinated alkyl variants only. That is a narrowing constraint compared with generic Markush “C1–C6 fluoroalkyl.”
R′
- “R′ = a CnH2n+1 group where n = 0–6”
- This is a small alkyl/hydrogen allowance depending on the meaning of n=0 in the drafting:
- For n=0, the group would correspond to H-like or methyl/zero-length interpretation, but as written it permits the full range n=0 to 6.
- Net effect: R′ is moderately broad (seven discrete chain-length options).
X
- “X = an isotope of F, an isotope of Cl, an isotope of Br, an isotope of I, CH3, or Sn(R″1R″2R″3)”
- This is the single most expansive claim element because it covers:
- multiple halogen/radioisotope choices (including iodine isotopes)
- a non-radioactive CH3 option
- and a tin(alkyl aryl) substitution option
- For competitive infringement analysis: if an accused neuroprobe uses iodine isotopes at that position, it is within the intended radioimaging class.
R″1, R″2, R″3
- Each of R″1, R″2, R″3 is:
- “a CnH2n+1 group where n=1–6, or an aryl group”
- So each R″ position is:
- alkyl in six chain lengths (n=1..6) or
- an aryl group (unbounded aryl identity by the claim language)
- This creates breadth specifically for any embodiment where X = Sn(R″1R″2R″3).
Y
- “Y = H”
- This is a fixed constraint that removes alternatives at the Y position.
Bottom-line on scope breadth
- Narrowing constraints: R fixed to monofluoroalkyl with n=18 or 19; Y fixed to H.
- Broad constraints: R′ (0–6), X (many isotope and chemical options), aryl/alkyl breadth at R″ positions.
Do dependent claims 2-4 and 6-8 meaningfully narrow scope or just pick isotopes?
Dependent claims select among iodine isotopes for X:
- ^123I (claims 2 and 6)
- ^125I (claims 3 and 7)
- ^131I (claims 4 and 8)
Practical claim effect
- If an accused product uses the same core scaffold but uses iodine at the defined X position with one of those isotopes, it is captured directly by these dependents.
- Even without dependents, the independents already allow “X = an isotope of … I” generically, so the dependents are best read as:
- claim strengthening for the most commercially common iodine radionuclides used in nuclear medicine probes
- and as fallback scope when defending against certain non-iodine or non-radioiodinated design-around attempts.
Litigation-style reading (functional)
- Independents define a class of iodinated neuroprobes.
- Dependents define specific embodiments by radioisotope, which often matters in:
- validity attacks on definiteness or enablement for specific radionuclides
- and infringement proof when labeling, radiochemistry reports, or imaging protocols identify the isotope used.
What does “mapping monoamine reuptake sites” add to claim scope and infringement?
The claims include a purpose/functional clause: “for mapping monoamine reuptake sites.”
How this can operate legally
Depending on claim construction practice in the relevant jurisdiction:
- The function may be treated as a statement of intended use that does not limit structural coverage, or
- it may provide an additional limitation if it is tied to how the probe is used in practicing the invention.
Business-relevant takeaway for product design
Even if the structure falls within the formula, a defendant could attempt to argue that their compound is not used “for mapping monoamine reuptake sites.” In practice, proof typically relies on:
- clinical or preclinical use disclosures
- labeling, IFUs, investigator brochures
- imaging protocols in published studies and regulatory filings
For an investor or licensing party, the functional clause increases risk for a company whose compound is structurally similar but targeted to a different biological target.
What formulations are covered: radiolabeled composition or just the labeled molecule?
The claim language is directed to an “iodinated neuroprobe” defined by formula and isotope at X. It does not expressly recite:
- dosage form
- formulation excipients
- sterilization or preparation parameters
- kit format
As drafted, the primary coverage is the radiolabeled chemical entity/scaffold (the “probe” itself). That typically captures:
- the active radioiodinated species
- embodiments where the rest of the radioisotope identity is reflected by X
A separate patent portfolio would be expected for:
- radiopharmaceutical formulation/process
- stability, delivery systems, or kit components
- synthesis and purification methods
- specific sterilized vials, labeling, or kit manufacturing
Without additional document context, the safest scope conclusion is that 5,310,912 is entity-focused rather than formulation-kit focused.
How strong is the patent estate around US 5,310,912 based on claim architecture?
Within the claim text you provided, strength indicators are:
Indicators of strength
- Breadth in X: includes iodine isotopes at the key position plus other isotopes/chemistries, which makes partial design-arounds harder.
- Fallback dependent claims: explicit coverage for ^123I, ^125I, ^131I.
- Markush generality: R″ positions allow multiple alkyl/aryl combinations for any tin-bearing variant.
Indicators of vulnerability
- Hard constraint on R: R is limited to monofluoroalkyl with n=18 or 19. If competitors use a different fluoroalkyl chain length or a non-fluorinated lipophilic group, they can fall outside the literal scope.
- Y fixed to H: eliminates substitution at that site.
Net: what “design-around” would likely work
To avoid literal infringement, a designer would focus on changing at least one of the claim-critical anchors:
- R chain-length/identity (not n=18 or 19 monofluoroalkyl), and/or
- removing the iodine isotope at X as required by the “iodinated” scaffold,
- or changing the substitution pattern implied by the distinct formulas in claims 1 vs 5.
What patent landscape issues matter for enforcement: entity similarity vs use vs isotope selection?
With the information provided (only claims), enforcement will typically hinge on three axes:
1) Structural matching to the formula
- Does the competitor’s probe map onto the same scaffold and Markush positions, especially R and Y?
2) Radioisotope proof at X
- If X is iodine, identify the isotope used clinically (often discoverable via regulatory materials, imaging protocols, or product-specific documentation).
3) Intended use evidence
- If a company argues they are not using the probe “for mapping monoamine reuptake sites,” the evidentiary record becomes important.
How do companies choose around claims like these: likely technical or commercial levers?
Given the claim structure, the most actionable design levers are:
- Alter R: avoid the long-chain monofluoroalkyl where n=18 or 19.
- Alter X: use a different positioning such that X is not iodine isotope in the recited formula.
- Substitution at Y: change Y away from H (if chemically feasible).
- Target strategy: develop probes for related but distinct transporters or receptors, and align labeling/purpose away from “monoamine reuptake sites.”
From a commercial standpoint, companies also align with:
- availability of the radionuclide
- regulatory pathway specifics
- supply chain for radioisotopes (operational realities can influence which isotope is used)
Key Takeaways
- US 5,310,912 covers iodinated neuroprobes for mapping monoamine reuptake sites, defined by a Markush structural formula with fixed Y=H and a constrained lipophilic anchor R (monofluoroalkyl with n=18 or 19).
- The claims are broad at X, allowing multiple halogen isotopes and specifically supporting iodine isotopes as required embodiments.
- Dependent claims 2–4 and 6–8 lock in the most common iodine radionuclides: ^123I, ^125I, and ^131I.
- The strongest literal-infringement risk is for products using the same scaffold with iodine at X and R matching n=18 or 19 monofluoroalkyl.
- The most likely literal design-arounds target the R anchor and/or the structural placement corresponding to X and Y.
FAQs
1) Can a non-iodinated analog infringe US 5,310,912 if it still maps monoamine reuptake sites?
Literal scope depends on meeting the formula where “X” is defined to include iodine isotopes; non-iodinated analogs would generally miss the “iodinated neuroprobe” structure requirement unless their “X” still falls within the claim options.
2) Does using ^124I instead of ^123I/^125I/^131I avoid the dependents?
It avoids the dependents that explicitly recite ^123I/^125I/^131I, but it may still fall within independents if “X” qualifies as “an isotope of … I” as drafted.
3) If a competitor uses the scaffold but changes the monofluoroalkyl chain length, is there still infringement risk?
The claims appear to constrain R to monofluoroalkyl with n=18 or 19, so changing chain length is a primary literal design-around path.
4) Are formulation patents covered by this patent or only the radiolabeled chemical entity?
The provided claims focus on the iodinated neuroprobe structure and isotope selection; they do not expressly recite excipients, kits, or dosage forms.
5) What evidence would most directly support infringement for a radiolabeled probe under these claims?
Structural identity to the formula and proof of the iodine isotope at X used in the labeled product, plus evidence that it is used for mapping monoamine reuptake sites.
References (APA)
- United States Patent 5,310,912.
